J0178Aflibercept injection
Published CMS Medicare Part B payment-limit context for J0178, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$743.605
per 1 MG · Medicare Part B
Up 1.6%from $731.885 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$834.5933$719.2717
2024-Q4: $821.98; 2025-Q1: $801.065; 2025-Q2: $795.861; 2025-Q3: $790.037; 2025-Q4: $771.558; 2026-Q1: $763.901; 2026-Q2: $731.885; 2026-Q3: $743.605
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Aflibercept ingredient family (FDA data as of August 20, 2026).
Eylea
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Aflibercept presentations
3 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J0177 | Inj, aflibercept hd, 1 mg | $298.683 per 1 MG | $301.177 per 1 MG | Down 0.8% | ||
| J9400 | Inj, ziv-aflibercept, 1mg | $8.674 per 1 MG | $8.608 per 1 MG | Up 0.8% | ||
| Q5147 | Inj, aflibercept-ayyh, 1 mg | $803.255 per 1 MG | $821.396 per 1 MG | Down 2.2% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.